AT&T will release third quarter results before the New York Stock Exchange opens on October 21, 2026, with a conference call at 8:30 a.m. ET and a webcast on its investor relations site, according to the company announcement dated August 27. Second quarter figures …
Spotify reports on Thursday, October 22, 2026, before the market opens, with a management Q&A at 8:00 a.m. ET submitted through an online tool, according to the company announcement. Third quarter 2026 guidance and consensus were not verified, so none is cited. The year-ago …
Eli Lilly (NYSE:LLY) closed at USD 1,251.61 inside a 52-week range of USD 783.85 to USD 1,292.65, about 3.2 percent below the high (simple arithmetic on two published numbers). No company announcement explains the jump. Published market data points to a rotation, with large …
Sales were USD 25.4 billion, up 5.9 percent, with the United States up 9.1 percent and international up 1.5 percent. Innovative Medicine carried the quarter, while MedTech missed estimates in published data despite gains in electrophysiology, Shockwave, contact lenses and trauma. Reported EPS of …
At second quarter results on July 16, 2026, Abbott raised full-year adjusted EPS guidance to USD 5.45 to USD 5.60 from USD 5.38 to USD 5.58 and reaffirmed comparable sales growth of 6.5 to 7.5 percent. Chairman and chief executive Robert Ford expects accelerating …
Elevance Health (NYSE:ELV) raised its 2026 adjusted EPS floor to at least USD 27.00 on July 15, 2026, and gave no third quarter guidance. A year earlier, third quarter adjusted EPS was reported at USD 6.03 against a consensus of USD 4.94. The stock …
Pfizer rose 0.79 percent to USD 29.44 on October 15, 2026, inside a 52-week range of USD 23.62 to USD 29.88, for a market value near USD 167.8 billion. Under the Section 232 framework, patented drugs face 100 percent unless a company has a …
Star Ratings are the federal quality scores that decide whether Medicare Advantage plans earn bonus payments, so a better score feeds directly into revenue. The company said 95 percent of its members are in plans rated 4 stars or above for 2027, and the …
Verastem released data on October 14, 2026 from a Phase 1/2 trial of VS-7375, an oral drug that binds both the active and inactive states of the KRAS G12D protein. In metastatic pancreatic cancer, 22 evaluable patients received 900 mg daily. The six-month progression-free …
ARO-MAPT is a subcutaneous RNA interference medicine that silences the gene producing tau, a protein that forms tangles in Alzheimer's disease. In the early study, healthy volunteers received one of three doses. Tau fell 40 percent at 2.1 mg/kg and 69 percent at 6.4 …